An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer-Reference-Cited by-同舟云学术

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

Published:2011-01 Issue:1 Volume:120 Page:38-42
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Rose Peter G.,Monk Bradley J.,Provencher Diane,Hartney Jean,Legenne Philippe,Lane Stephen

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference28 articles.

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology™. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. V.2.2010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf. Accessed June 7, 2010.

2. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study;Ozols;J Clin Oncol,2003

3. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;du Bois;J Natl Cancer Inst,2003

4. Cancer of the ovary;Kosary,2007

5. Is there a “best” choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?;Cannistra;J Clin Oncol,2002

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer;Anticancer Research;2018-12-27

2. Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer;Journal of Chemotherapy;2016-03-03

3. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience;Taiwanese Journal of Obstetrics and Gynecology;2015-02

4. Major clinical research advances in gynecologic cancer in 2012;Journal of Gynecologic Oncology;2013

5. Chemotherapeutic management of recurrent ovarian cancer;Advances in Ovarian Cancer Management;2012-03